Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial

Overview of attention for article published in European Child & Adolescent Psychiatry, April 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

So far, Altmetric has seen 14 X posts from 13 X users, with an upper bound of 39,046 followers.

RT @ESCAPonline: ECAP article: #Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial #ASD #auti…

RT @ESCAPonline: ECAP article: #Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial #ASD #auti…

ECAP article: #Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial #ASD #autism https://t.co/pTMxqoUERd

RT @baclofenews: Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial https://t.co/u7OBqZ1jdC #…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 10 additional X posts.